Search





Search





Markets
/
Stocks
/
jspr
/

Jasper Therapeutics Inc

JSPR

Add to Watchlist

0.630USD

+0.009+1.48%

Close 07-31 16:00（ET）Quotes delayed by 15 min

20.96MMarket Cap

LossP/E TTM

Jasper Therapeutics Inc

0.630

+0.009+1.48%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

JSPR Cash Flow Statement

You can access the annual and quarterly cash flow statements of Jasper Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

FY2020Q4

FY2020Q3

Operating cash flows (indirect method)

Cash flow from continuing operating activities

36.31%-14.55M

-3.47%-21.87M

-20.97%-17.00M

-32.30%-15.45M

-45.16%-22.84M

-28.25%-21.13M

-17.29%-14.05M

12.00%-11.68M

-52.26%-15.74M

-30.31%-16.48M

-24.25%-11.98M

-41.86%-13.27M

27.28%-10.34M

13.29%-12.65M

-35.66%-9.64M

-61.56%-9.36M

-129.43%-14.21M

-170.42%-14.58M

10.33%-7.11M

---5.79M

---6.20M

---5.39M

---7.93M

Net income from continuing operations

94.47%-1.17M

62.58%-9.10M

-0.53%-18.74M

-83.25%-26.72M

-54.73%-21.24M

-46.68%-24.32M

-6.23%-18.64M

9.31%-14.58M

3.73%-13.73M

-25.51%-16.58M

-47.89%-17.54M

-54.56%-16.08M

-546.13%-14.26M

-45.87%-13.21M

-247.68%-11.86M

-23.65%-10.40M

77.37%-2.21M

9.31%-9.06M

68.48%-3.41M

---8.41M

---9.75M

---9.99M

---10.82M

Operating gains losses

-92.47%21.00K

472.24%1.40M

-57.67%229.00K

-13.71%258.00K

-3.13%279.00K

-13.43%245.00K

96.01%541.00K

8.73%299.00K

5.11%288.00K

3.66%283.00K

2.99%276.00K

26.15%275.00K

26.85%274.00K

40.72%273.00K

103.03%268.00K

651.72%218.00K

881.82%216.00K

--194.00K

--132.00K

--29.00K

--22.00K

----

--0.00

Other non-cash items

-4.15%185.00K

153.85%330.00K

1797.60%2.37M

162.50%315.00K

66.38%193.00K

16.07%130.00K

17.92%125.00K

17.65%120.00K

17.17%116.00K

19.15%112.00K

17.78%106.00K

7.37%102.00K

76.79%99.00K

161.11%94.00K

390.32%90.00K

7.95%95.00K

-41.67%56.00K

71.43%36.00K

---31.00K

--88.00K

--96.00K

--21.00K

--0.00

Change in working capital

-12.33%-4.36M

-1270.88%-9.73M

-109.63%-187.00K

786.03%8.88M

-7.86%-3.88M

158.40%831.00K

-52.89%1.94M

-31.37%1.00M

-480.66%-3.60M

-21.52%-1.42M

129.53%4.12M

28.07%1.46M

139.20%946.00K

59.44%-1.17M

-33.12%1.79M

-48.44%1.14M

-523.51%-2.41M

-2409.60%-2.89M

226.37%2.68M

--2.21M

---387.00K

--125.00K

---2.12M

-Change in receivables

----

-100.00%0.00

100.00%0.00

--0.00

--663.00K

---663.00K

--0.00

-100.00%0.00

--0.00

--600.00K

----

--0.00

-Change in prepaid expenses

2.99%-195.00K

-22.35%-2.29M

52.82%-209.00K

3382.14%919.00K

-192.20%-201.00K

-167.14%-1.87M

-131.55%-443.00K

-107.93%-28.00K

175.17%218.00K

48.42%-700.00K

38.87%1.40M

-61.92%353.00K

-7.81%-290.00K

29.54%-1.36M

162.60%1.01M

713.16%927.00K

65.73%-269.00K

-421.00%-1.93M

160.44%385.00K

--114.00K

---785.00K

--600.00K

---637.00K

-Change in other current assets

-87.50%36.00K

-80.83%37.00K

-72.00%42.00K

30.77%340.00K

460.00%288.00K

120.71%193.00K

341.18%150.00K

-7.14%260.00K

-335.29%-80.00K

-331.48%-932.00K

0.00%34.00K

723.53%280.00K

0.00%34.00K

37.75%-216.00K

-94.92%34.00K

105.08%34.00K

--34.00K

-16.44%-347.00K

2377.78%669.00K

---669.00K

--0.00

---298.00K

--27.00K

-Change in other current liabilities

----

100.00%0.00

-101.94%-32.00K

60.00%-16.00K

-114.55%-16.00K

-1700.00%-16.00K

1716.67%1.65M

-139.22%-40.00K

154.73%110.00K

0.00%1.00K

49.50%-102.00K

5000.00%102.00K

---201.00K

--1.00K

---202.00K

--2.00K

Cash from non-recurring investing activities

Cash from operating activities

36.31%-14.55M

-3.47%-21.87M

-20.97%-17.00M

-32.30%-15.45M

-45.16%-22.84M

-28.25%-21.13M

-17.29%-14.05M

12.00%-11.68M

-52.26%-15.74M

-30.31%-16.48M

-24.25%-11.98M

-41.86%-13.27M

27.28%-10.34M

13.29%-12.65M

-35.66%-9.64M

-61.56%-9.36M

-129.43%-14.21M

-170.42%-14.58M

10.33%-7.11M

---5.79M

---6.20M

---5.39M

---7.93M

Investing cash flow

Net cash from continuing investing activities

100.00%0.00

-100.00%0.00

-100.64%-1.00K

-116.00%-4.00K

-66.96%76.00K

--274.00K

1327.27%157.00K

-3.85%25.00K

180.49%230.00K

-100.00%0.00

-95.47%11.00K

-10.34%26.00K

-88.47%82.00K

-52.77%222.00K

-15.33%243.00K

-96.98%29.00K

--711.00K

--470.00K

--287.00K

--960.00K

----

--0.00

Capital expenditures

----

-100.00%0.00

-95.54%7.00K

----

-58.26%96.00K

--274.00K

1327.27%157.00K

-3.85%25.00K

180.49%230.00K

-100.00%0.00

-95.47%11.00K

-10.34%26.00K

-88.47%82.00K

-52.77%222.00K

-15.33%243.00K

-96.98%29.00K

--711.00K

--470.00K

--287.00K

--960.00K

----

--0.00

Net cash flow from disposal of fixed assets

100.00%0.00

-100.00%0.00

-100.64%-1.00K

-116.00%-4.00K

-66.96%76.00K

--274.00K

1327.27%157.00K

-3.85%25.00K

180.49%230.00K

-100.00%0.00

-95.47%11.00K

-10.34%26.00K

-88.47%82.00K

-52.77%222.00K

-15.33%243.00K

-96.98%29.00K

--711.00K

--470.00K

--287.00K

--960.00K

----

--0.00

Cash from non-current investing activities

Net cash flow from investing activities

-100.00%0.00

100.00%0.00

100.64%1.00K

116.00%4.00K

66.96%-76.00K

---274.00K

-1327.27%-157.00K

3.85%-25.00K

-180.49%-230.00K

100.00%0.00

95.47%-11.00K

10.34%-26.00K

88.47%-82.00K

52.77%-222.00K

15.33%-243.00K

96.98%-29.00K

---711.00K

---470.00K

---287.00K

---960.00K

----

--0.00

Financing cash flow

Cash flow from continuous financing activities

----

-198.55%-340.00K

315322.22%28.39M

3304.97%6.16M

-100.00%0.00

227.31%345.00K

-75.00%9.00K

159.34%181.00K

-53.36%47.35M

-1067.86%-271.00K

3500.00%36.00K

-2446.15%-305.00K

780753.85%101.51M

103.08%28.00K

-100.00%1.00K

102.17%13.00K

-99.88%13.00K

-108.41%-909.00K

--91.73M

---600.00K

--10.75M

--10.80M

--0.00

Net cash flow from common stock issuance/repurchase

----

-93.65%20.00K

--514.00K

13595.56%6.16M

-100.00%0.00

1025.00%315.00K

--0.00

25.00%45.00K

-53.49%47.20M

0.00%28.00K

--0.00

--36.00K

--101.48M

--28.00K

----

Net cash flow from preferred stock issuance/repurchase

----

--0.00

-100.00%0.00

--0.00

--10.75M

--0.00

Proceeds from stock option exercised by employees

----

-100.00%0.00

--30.00K

-75.00%9.00K

-57.50%136.00K

381.25%154.00K

--0.00

3500.00%36.00K

2361.54%320.00K

146.15%32.00K

-100.00%0.00

-99.24%1.00K

-80.88%13.00K

550.00%13.00K

-37.74%33.00K

--132.00K

--68.00K

--2.00K

--53.00K

--0.00

Proceeds from issuance of warrants

----

--1.00K

----

Net cash flow from other financing activities

----

---360.00K

--27.87M

----

---299.00K

--0.00

---661.00K

----

100.00%0.00

----

---943.00K

--91.59M

---668.00K

----

--0.00

Net cash from non-recurrent financing activities

Net cash from financing activities

----

-198.55%-340.00K

315322.22%28.39M

3304.97%6.16M

-100.00%0.00

227.31%345.00K

-75.00%9.00K

159.34%181.00K

-53.36%47.35M

-1067.86%-271.00K

3500.00%36.00K

-2446.15%-305.00K

780753.85%101.51M

103.08%28.00K

-100.00%1.00K

102.17%13.00K

-99.88%13.00K

-108.41%-909.00K

--91.73M

---600.00K

--10.75M

--10.80M

--0.00

Net cash flow

Beginning cash balance

-59.60%29.11M

-44.77%51.32M

-62.77%39.93M

-58.60%49.22M

-17.47%72.05M

-10.90%92.92M

-7.74%107.24M

-8.42%118.89M

125.78%87.30M

103.02%104.28M

89.82%116.23M

83.31%129.82M

-54.53%38.67M

-49.27%51.37M

258.03%61.23M

197.80%70.82M

321.37%85.05M

585.37%101.25M

-24.66%17.10M

--23.78M

--20.18M

--14.77M

--22.70M

Current period cash flow changes

36.30%-14.55M

-6.43%-22.21M

179.55%11.39M

20.31%-9.29M

-172.30%-22.84M

-22.88%-20.86M

-19.86%-14.32M

14.22%-11.66M

-65.35%31.59M

-33.70%-16.98M

-21.10%-11.95M

-41.75%-13.59M

740.59%91.15M

21.62%-12.70M

-111.72%-9.86M

-43.55%-9.59M

-495.58%-14.23M

-399.52%-16.20M

1161.54%84.15M

---6.68M

--3.60M

--5.41M

---7.93M

Ending cash balance

-70.41%14.56M

-59.60%29.11M

-44.77%51.32M

-62.77%39.93M

-58.60%49.22M

-17.47%72.05M

-10.90%92.92M

-7.74%107.24M

-8.42%118.89M

125.78%87.30M

103.02%104.28M

89.82%116.23M

83.31%129.82M

-54.53%38.67M

-49.27%51.37M

258.03%61.23M

197.80%70.82M

321.37%85.05M

585.37%101.25M

--17.10M

--23.78M

--20.18M

--14.77M

Free cash flow

36.31%-14.55M

-3.00%-21.87M

-18.66%-17.00M

-30.61%-15.46M

-44.93%-22.84M

-27.06%-21.23M

-19.57%-14.33M

10.89%-11.84M

-52.12%-15.76M

-31.28%-16.71M

-21.45%-11.98M

-38.38%-13.28M

27.25%-10.36M

16.78%-12.73M

-30.18%-9.87M

-57.93%-9.60M

-99.05%-14.24M

---15.29M

4.40%-7.58M

---6.08M

---7.16M

----

---7.93M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Jasper Therapeutics Inc Generate?



Jasper Therapeutics Inc generated -77.16M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Jasper Therapeutics Inc's Operating Cash Flow Change Year Over Year?



Jasper Therapeutics Inc's operating cash flow increased by -23.26% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Jasper Therapeutics Inc Spend on Capital Expenditures?



Jasper Therapeutics Inc spent 7.00K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Jasper Therapeutics Inc's Financing Cash Flow Changed?



Jasper Therapeutics Inc used 34.21M in financing activities in the latest quarter.

What is free cash flow and why does it matter for JSPR?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Jasper Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -77.17M reflecting a -22.19% change from the previous year.